Which drug should be used for treating mild to moderate chronic depression? Evidence update - Summary of a Cochrane Review by Effective Health Care Research Consortium
Evidence Update 
May 2006 Mental Health Series 
Inclusion criteria 
Studies:  
Randomized and quasi-randomized controlled trials. 
Participants: 
People with a primary diagnosis of dysthymia (mild to 
moderate depression lasting two years or more), or 
with an alternative non-major depression diagnosis 
where the illness was of at least two years’ duration. 
Intervention: 
Drugs used for treating depression.  
Outcomes: 
Improvement in symptoms; resolution of symptoms; 
treatment acceptability (number of drop outs and 
exclusions post-randomization); side effects; relapse; 
quality of life.  
Results 
• Fourteen trials with a total of 1659 participants 
were included; allocation was adequately 
concealed in three trials.  
• Trials examining the effectiveness of different 
antidepressants in head-to-head comparisons were 
limited; there is insufficient evidence to decide 
which drugs are most effective for improving or 
resolving the symptoms of mild depression. 
• Although some small trials examined side effects 
and acceptability of treatment, these were also 
limited and there is insufficient evidence to clearly 
identify differences between drug classes.    
Which drug should be used for treating mild to 
moderate chronic depression? 
It is not known which are the safest and most effective drugs 
for treating mild to moderate chronic depression. 
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Authors’ conclusions 
Implications for practice:  
Trials comparing different antidepressant drugs were too small to detect clinically important differences in 
treating dysthymia.  
Implications for research: 
Well-designed trials that examine the comparative effectiveness and safety of drugs for dysthymia are needed.  
The Cochrane Database of Systematic Reviews is available from www.wiley.com, and free for eligible countries through www.healthinternetwork.org.  
Non-response to treatment: tricyclic antidepressant (TCA) versus other antidepressants  
